Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.

PMID:
29545067
2.

Reflex impairment and physiology as predictors of delayed mortality in recreationally caught yellowtail snapper (Ocyurus chrysurus).

Forrestal FC, McDonald MD, Burress G, Die DJ.

Conserv Physiol. 2017 Jun 8;5(1):cox035. doi: 10.1093/conphys/cox035. eCollection 2017.

3.

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.

O'Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, Hauswirth K, Cristiano LM, Forrestal F, Duda P.

Neurology. 2014 Jul 1;83(1):78-86. doi: 10.1212/WNL.0000000000000541. Epub 2014 Jun 4. Erratum in: Neurology. 2014 Aug 19;83(8):773.

4.

Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.

Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P.

J Neurol Sci. 2014 Jun 15;341(1-2):22-7. doi: 10.1016/j.jns.2014.03.035. Epub 2014 Mar 26.

PMID:
24731783
5.

Effects of acute relapses on neuropsychological status in multiple sclerosis patients.

Morrow SA, Jurgensen S, Forrestal F, Munchauer FE, Benedict RH.

J Neurol. 2011 Sep;258(9):1603-8. doi: 10.1007/s00415-011-5975-3. Epub 2011 Mar 8. Erratum in: J Neurol. 2011 Sep;258(9):1609.

PMID:
21384163
6.

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks.

Morrow SA, O'Connor PW, Polman CH, Goodman AD, Kappos L, Lublin FD, Rudick RA, Jurgensen S, Paes D, Forrestal F, Benedict RH.

Mult Scler. 2010 Nov;16(11):1385-92. doi: 10.1177/1352458510378021. Epub 2010 Aug 25.

PMID:
20739335
7.

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.

Rudick RA, O'Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, Goelz SE.

Ann Neurol. 2010 Sep;68(3):304-10. doi: 10.1002/ana.22107.

PMID:
20737514
8.
9.

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.

Neurology. 2006 Sep 26;67(6):944-53.

PMID:
17000959

Supplemental Content

Loading ...
Support Center